Leadership Changes

Breaking

Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD FDA Approves Guardant360 CDx Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup

NewsApr 15, 2026

Oryon Cell Therapies Appoints Dr. Burkhard Blank as Chief Medical Officer to Lead Clinical Development

Oryon Cell Therapies names Dr. Burkhard Blank as CMO to advance clinical-stage cell therapy programs and strengthen leadership team in biotechnology sector.

Dr. Sarah Mitchell

News by Topic

More News Topics

Press Releases

Analysis by Topic

More Analysis Topics

Whitepapers

Browse

By Region

Directory

By Region

For Suppliers

For Brands

Resources

Popular Topics

More Topics

Browse

About Us

Get in Touch

Quick Actions

Recent Searches

Popular Topics

Suggestions

Oryon Cell Therapies Appoints Dr. Burkhard Blank as Chief Medical Officer to Lead Clinical Development